Chronic kidney disease (CKD) is a persistent condition where the kidneys gradually lose their ability to function properly. Early on, many individuals experience few symptoms, but over time, the disease can lead to kidney failure and elevate the risk of heart problems. One of the primary goals in nephrology is developing treatments that slow down this progression.
A recent international study offers promising news. Researchers discovered that finerenone, a medication already prescribed for some patients with diabetic kidney disease, can also offer benefits to those with CKD who do not have diabetes. These findings were published in the New England Journal of Medicine.
The study, known as FIND-CKD, was led by Professor Hiddo Lambers Heerspink from the University Medical Center Groningen. It involved 1,584 adults from various countries who all had decreased kidney function and excess protein in their urine. The presence of protein in the urine is an early warning sign of kidney damage and often indicates a higher likelihood of disease progression. Therefore, reducing protein levels in the urine is a crucial treatment target.
Participants were assigned either finerenone or a placebo while continuing their existing kidney-protective therapies. The researchers tracked them for just over three years to compare changes in kidney health. Kidney function was assessed using estimated glomerular filtration rate (eGFR). Those taking finerenone experienced a slower decline in eGFR, meaning their kidneys maintained better function longer than those on the placebo.
In addition, the drug lowered the risk of severe kidney and cardiovascular complications. About 13.9% of patients on finerenone faced major kidney events, heart failure hospitalizations, or cardiovascular death, compared to 16.9% in the placebo group. An Especially notable benefit was the significant reduction in protein levels in the urine — finerenone decreased urinary protein by over 41% on average, whereas the placebo group saw only a roughly 9% reduction. More than half of the patients receiving finerenone achieved reductions of at least 30%, which is associated with a more favorable outlook for kidney health.
Previously, most large studies on finerenone focused on individuals with type 2 diabetes. This research indicates that the medicine may be effective for a broader population because more than half of all people with CKD do not have diabetes.
Importantly, the study reported no unexpected safety issues during treatment. However, patients should only take finerenone under medical supervision, as kidney function and blood potassium levels require careful monitoring.
Overall, this high-quality clinical trial provides compelling evidence that finerenone could become a valuable addition to the standard treatment options for non-diabetic CKD. Future guidelines and real-world experiences will help clarify which patient groups will benefit the most.
If you’re interested in diabetes prevention, consider reading about five vitamins that may help prevent complications, along with tips on managing high blood pressure and diabetes through healthy eating. For additional health insights, explore recent studies on vitamin D and type 2 diabetes, and learn which fruits might be better suited for individuals with the condition.